Ferring Pharmaceuticals

Focus: Ferring Pharmaceuticals is a small-molecule manufacturer headquartered in Buenos Aires with 5,000+ employees, focused on specialty pharmaceuticals across neurology and reproductive health. The company operates a mature, revenue-concentrated portfolio anchored by CLENPIQ (bowel cleansing) which represents 91% of revenue.

Neurology

Profile data last refreshed 10h ago · AI intelligence enriched 2w ago

Employees

5000+

Open Jobs

93+61 this month

Hot — 186 jobs added in 30d

Net +61 (186 new, 125 removed). Aggressive expansion phase.

2 recent layoff filings (12 mo) — 128 affected

10/1/2025 — Parsippany, NJ · 64 affected · Layoff
10/1/2025 — Parsippany, NJ · 64 affected · Layoff

Source: state DOL filings via Big Local News

Should You Work at Ferring Pharmaceuticals?

AI assessment

Ferring offers stable specialty pharma roles with a maturing product base and growing pipeline, but layoff activity and revenue concentration warrant careful diligence on team stability and long-term strategic direction.

Why Work Here

Stable, peak-generating products (CLENPIQ, NOCDURNA, FIRMAGON) provide predictable revenue and established market presence through 2030+

Data completeness

6/9 — Partial

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

4 in 5yr

MILPROSA

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

CLENPIQ

Bowel cleansing

$33M Part D

Peak11.6yr

Flagship product generating 91% of company revenue with 12+ years of patent exclusivity remaining; drives commercial hiring and profitability.

Help build intelligence for Ferring Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline across 29 programs with multiple Phase 3 candidates in fertility, gastroenterology, and endocrinology signals growth beyond current revenue concentration

Active hiring across commercial (20 roles), R&D (7), and medical affairs (5) indicates expansion despite recent layoffs in New Jersey

Watch Out For

128 employees laid off in October 2025 at Parsippany facility signals cost restructuring and organizational instability despite expansion headlines
Extreme revenue concentration (91% from single product CLENPIQ) with limited patent protection beyond 2030 creates succession risk and potential future restructuring
Active shortage of Desmopressin Acetate Spray and recent portfolio assessment terminating fertility trials suggest operational or strategic challenges

Generated by Claude from Ferring Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NOCDURNA

Nocturnal enuresis

$2M Part D

Peak3.8yr

Peak-stage product with ~4.5 years until LOE; minor revenue contributor but part of desmopressin franchise expansion efforts.

FIRMAGON

Prostate cancer (implied BPH indication in pipeline)

$1M Part D

Peak5.8yr

Peak-stage oncology asset with ~6.5 years of exclusivity; being explored in Phase 2 for BPH indication expansion.

DESMOPRESSIN ACETATE

Nephrogenic and central diabetes insipidus

$130K Part D

Post-LOE

Post-LOE generic formulation with minimal revenue; represents mature, commoditized segment of desmopressin portfolio.

ZOMACTON

Growth disorders

$68K Part D

LOE Approaching

Biologic approaching LOE with minimal current revenue; faces generic/biosimilar competition in growth hormone market.

ENDOMETRIN

Luteal phase support in reproductive medicine

$8K Part D

LOE Approaching

Vaginal insert approaching LOE with negligible Part D spending; recent biosimilar approval (Glenmark) indicates market erosion.

DDAVP

Diabetes insipidus, nocturnal enuresis

LOE Approaching

Formulation innovation (ambient-stable DDAVP) positioning for market advantage; currently in active shortage per FDA database.

MENOPUR

Fertility/assisted reproduction

LOE Approaching

Biologic gonadotropin for fertility; company terminated related trials in portfolio assessment, signaling deprioritization.

CERVIDIL

Cervical ripening, labor induction

LOE Approaching

Prostaglandin for obstetrics with Phase 3 program ongoing; part of reproductive health focus but maturity stage product.

LUTREPULSE KIT

Infertility (GnRH pulsatile pump)

LOE Approaching

Specialty device-drug combination for infertility; recent portfolio trial terminations suggest reassessment of fertility portfolio ROI.

Pipeline & Clinical Trials

EUFLEXXA™

Osteoarthritis, Knee

N/A

Clinical Trials (1)

NCT00379236A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee

N/A

mesalazine

Ulcerative Colitis

N/A

Clinical Trials (1)

NCT02261636Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment

N/A

No intervention

Infertility, Female

N/A

Clinical Trials (1)

NCT04876300MEDAM (Menopur Retrospective Data prograM)

N/A

Mesalazine

Ulcerative Colitis

N/A

Clinical Trials (1)

NCT01517607Mesalazine (PENTASA®) in Ulcerative Colitis

N/A

Sodium Picosulfate, Magnesium Oxide and Citric Acid

Bowel Cleansing

N/A

Clinical Trials (1)

NCT03631446Drug Use-Results Survey on Picoprep® Combination Powder

N/A

No intervention

Bowel Cleansing

N/A

Clinical Trials (1)

NCT04852120Compound Sodium Picosulfate Granules for Bowel Preparation in Chinese Population

N/A

hMG-HP/r-FSH

Sterility

N/A

Clinical Trials (1)

NCT01330771Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP

N/A

Other: Non intervention

Infertility, Female

N/A

Clinical Trials (1)

NCT04654039Post-Marketing Surveillance (PMS) Protocol of REKOVELLE Pre-Filled Pen (Follitropin Delta)

N/A

Fast Track to Fertility Algorithmic Text Messaging Platform

Infertility

N/A

Clinical Trials (1)

NCT07154888Fast Track to Fertility

N/A

hMG

Infertility

N/A

Clinical Trials (1)

NCT01354834Assessment of the Effectiveness of Menopur in Intrauterine Insemination

N/A

Comprehensive Chromosome Screening

Infertility

N/A

Clinical Trials (1)

NCT02032264Next Generation Sequencing Screening for Embryonic Ploidy Status

N/A

whole-genome sequencing

Diminished Ovarian Reserve

N/A

Clinical Trials (1)

NCT04711772Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve

N/A

Study of the Cleavage of the Egg in Relation to the Stimulation Treatment

Female Infertility

N/A

Clinical Trials (1)

NCT01674894Study of the Cleavage of the Egg in Relation to the Stimulation Treatment

N/A

Blood sample

AMH

N/A

Clinical Trials (1)

NCT04927676Hormones in Hypogonadotropic Hypogonadism

N/A

INVOcell

Infertility

N/A

Clinical Trials (1)

NCT04246268Assessment of the INVOcell Intravaginal Culture System

N/A

hMG-HP

Sterility

N/A

Clinical Trials (1)

NCT01330784Assessment of the Therapeutic Utility of hMG-HP

N/A

AMPLEX

Arthrodesis Surgery Involving the Hindfoot or Ankle

N/A

Clinical Trials (1)

NCT03028415AMPLEX Ankle Fusion and Hindfoot

N/A

REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted

Infertility

N/A

Clinical Trials (1)

NCT06545877REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)

N/A

Euflexxa

Meniscus Tear

N/A

Clinical Trials (1)

NCT01256788Post-op Treatment With Hyaluronic Acid Injections

N/A

Follicle Stimulating Hormone (FSH) Receptor Polymorphisms in In-Vitro Fertilization Cycles.

Infertility

N/A

Clinical Trials (1)

NCT01002885Follicle Stimulating Hormone (FSH) Receptor Polymorphisms in In-Vitro Fertilization Cycles.

N/A

AURORA-Donor

Infertility

N/A

Clinical Trials (1)

NCT06280677Aurora Test for ART Donor Patients (AURORA-Donor)

N/A

Menotrophin

Infertility

N/A

Clinical Trials (1)

NCT02935335A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur®

N/A

Highly purified menotropin

Ovarian Hyperstimulation Syndrome (OHSS)

N/A

Clinical Trials (1)

NCT01703728Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.

N/A

Low FODMAP diet

eHealth

N/A

Baseline EpiNP survey

Nocturnal Polyuria

N/A

Clinical Trials (1)

NCT04125186A Cross-Functional, Population-Representative, Web-Based, Epidemiologic Study to Estimate the Prevalence and Burden of Nocturia Due to Nocturnal Polyuria in the US

N/A

Oxidative stress

Fertility Preservation

N/A

Clinical Trials (1)

NCT05372549Correlation of Oxidative Stress and Oocyte Quality in Fertility Preservation

N/A

hMG-HP

STERILITY

N/A

Clinical Trials (1)

NCT01331720Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation

N/A

hMG-HP

Sterility

N/A

Clinical Trials (1)

NCT01331733Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist

N/A

A Study of Minirin Melt in 24 Months Treatment in Patients With Nocturia

Nocturia

N/A

Clinical Trials (1)

NCT01552395A Study of Minirin Melt in 24 Months Treatment in Patients With Nocturia

N/A

PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)

Pre-eclampsia

N/A

Clinical Trials (1)

NCT07263490PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)

N/A

SyBeMeP

Nocturia

N/A

Clinical Trials (1)

NCT01576900The Effect of Combined Systematized Behavioural Modification Education Program (SyBeMeP) With DDAVP in Patients With Nocturia

N/A

Coenzyme Q10 co treatment

Poor Ovarian Response

N/A

Clinical Trials (1)

NCT00878124How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome

N/A

Embryo cryopreservation

Infertility

N/A

Clinical Trials (1)

NCT00963625Comparison of Transfers of Fresh and Thawed Embryos in Normal Responder Patients

N/A

Presence of Toxins from Smoking in the Follicular Fluid of Women Undergoing Intracytoplasmic Sperm I

Exposure to Toxins from Smoking

N/A

Clinical Trials (1)

NCT03414567Presence of Toxins from Smoking in the Follicular Fluid of Women Undergoing Intracytoplasmic Sperm Injection Treatment

N/A

Menotrophin

Infertility

N/A

Clinical Trials (1)

NCT02835469A Study on Efficacy and Safety of Menopur® Multidose in Korean Female Patients With Infertility

N/A

Coenzyme Q10 concomitant treatment

Aneuploidy

N/A

Clinical Trials (1)

NCT01048385The Effect of Co Enzyme Q10 Together With Fertility Drugs on Pregnancy Outcome of in Vitro Fertilization

N/A

Inflammatory Bowel Disease in South Eastern Norway

Colitis, Ulcerative

N/A

Single Embryo Transfer

Infertility

N/A

Clinical Trials (1)

NCT01408433Single Embryo Transfer of a Euploid Embryo Versus Double Embryo Transfer

N/A

Analysis of Toxins in Follicle Fluid

Environmental Exposure to Harmful Algae and Toxins

N/A

Clinical Trials (1)

NCT01385605Analysis of Toxins in Follicle Fluid

N/A

Low Residue Diet

Colonoscopy Preparation

N/A

Clinical Trials (1)

NCT04150133Effects and Tolerability With Clenpiq and Low Residue Diet

N/A

PROPESS Cohort

Cervical Ripening

N/A

Clinical Trials (1)

NCT04773314General Drug Use-results Survey on PROPESS Vaginal Inserts in Treatment for Initiation of Cervical Ripening in Patients at Term (From 37 Completed Weeks of Gestation)

N/A

IVF/ICSI treatment

Infertility

N/A

Clinical Trials (1)

NCT02129998The Role of Progesterone and PIF for Successful Implantation and On-going Pregnancy in Assisted Reproductive Technology

N/A

Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients

Nasopharyngeal Cancer

N/A

Clinical Trials (1)

NCT04340024Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients

N/A

AdhesioRT

Fertility

N/A

Clinical Trials (1)

NCT04840121Personalizing Window of Implantation During Frozen Embryo Transfer

N/A

A Study of Minirin Melt in Patients With Nocturia

Nocturia

N/A

Clinical Trials (1)

NCT01212224A Study of Minirin Melt in Patients With Nocturia

N/A

menotropin

Infertility

N/A

Clinical Trials (1)

NCT02018159An Explorative Prospective Observational Study to Describe Morphokinetic De-selection Parameters in Human Embryos

N/A

A Study of Minirin Melt in Patients With Nocturia

Nocturia

N/A

Clinical Trials (1)

NCT01222598A Study of Minirin Melt in Patients With Nocturia

N/A

Gelronate

Radiation Dermatitis

N/A

Clinical Trials (1)

NCT03941665Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients

N/A

Carbetocin

N/A

Clinical Trials (1)

NCT03959436Database Evaluating Outcomes of Using Carbetocin as the Primary Uterotonic Following Cesarean Delivery

N/A

Somatropin

Growth Hormone Deficiency

N/A

Clinical Trials (1)

NCT01731028Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton®

N/A

Interview Prep Quick Facts

Founded: 2024

Portfolio: 42 approved products, 148 clinical trials

Top TAs: Oncology, Immunology, Metabolic Diseases

Publications: 25 in PubMed

Open Roles: 93 active jobs

Portfolio Health

Pre-Launch1 (2%)

Peak5 (12%)

LOE Approaching22 (52%)

Post-LOE14 (33%)

42 total products

Therapeutic Area Focus

Oncology

3 marketed71 pipeline

Immunology

1 marketed32 pipeline

Metabolic Diseases

18 marketed3 pipeline

Women's Health

2 marketed17 pipeline

Hiring Trend

Actively Hiring

Open Roles

+31

Added

-11

Filled/Removed

Based on last 4 crawl cycles

Risk Signals

WARN Act Layoff Notices (2)

2025-10-01

64 employees affected— Parsippany, NJ

2025-10-01

64 employees affected— Parsippany, NJ

Source: state DOL filings, aggregated via Big Local News

1 active drug shortage

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy.

Journal of medical economics

2026

PMID:41780023

Feed injection-enabled reversed phase liquid chromatography for simplified analysis of lipophilic drugs and formulations.

Gastroenterology

2 marketed8 pipeline

Nephrology

3 marketed

Cardiovascular

3 pipeline

128 employees laid off October 1, 2025 at Parsippany, NJ manufacturing/commercial hub; subsequently announced May 2026 FDA-approved manufacturing expansion at same location, indicating restructuring rather than closure.

Recent dual 64-person layoffs (128 total) at primary U.S. hub alongside expansion plans create uncertainty about team stability; interview carefully on post-restructuring team dynamics and role security.

Journal of chromatography. A

2026

PMID:41818842

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Ferring Pharmaceuticals

Should You Work at Ferring Pharmaceuticals?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (9)

Key Products by Revenue

Other Products (5)

Pipeline & Clinical Trials

Recent News · Ferring Pharmaceuticals(7)

Open Jobs (93)

Regional Sales Manager, Interventional Spine - South

Quality Learning Systems Specialist

Facilities Engineer

Regional Sales Manager, Interventional Spine - Northeast

Key Account Manager

Scientist - I (Process Expert) – Late Stage CMC

Regional Sales Director, Uro-Oncology - Mid-West

Medical Science Liaison, Uro-Oncology – Northeast

Sales Specialist, Uro-Oncology - Chicago North, IL

Senior Manager, Marketing - Interventional Spine

Director, Marketing - Interventional Spine

Director, Strategic Pricing

Specialist, Shutdown Coordinator

National Sales Director, Interventional Spine

Associate General Counsel, Business Development

Medical Science Liaison, Reproductive Medicine - Southwest

People Solution Opex Analyst

Associate Director, Medical Outcomes Value Liaison- Central

Director, Quality Control

Join our Talent Community for Medical Science Liaisons in Interventional Spine

Join our Talent Community for Key Account Managers in IV Spine

Join our Talent Community for Sales Professionals in IV Spine

Join our Talent Community for Regional Managers in IV Spine

Join our Talent Community for Clinical Specialists in IV Spine

Senior Manager, Medical Science Liaison, Uro-Oncology – Northwest

Hiring Trend

Risk Signals

WARN Act Layoff Notices (2)

Research Publications(10)